Animal Health

Brains Bio is an early-mover in veterinary cannabinoid market with strong overlap in R&D, targeting co-development opportunities with accelerated routes to market.

Built on Clinical Science

Leveraging human clinical data and formulations to accelerate veterinary product development.

Developing therapeutics for chronic and acute conditions and OTC wellness products for everyday health support.

Companion animals. Dogs and cats, where cannabinoid therapies for chronic and acute conditions are being actively developed and evaluated, and where consumer demand for pharmaceutical-grade wellness products continues to grow.
Performance species. Horses, camels and falcons, where cannabinoid therapies are being developed and evaluated for applications relevant to animal welfare and performance support. These species represent high-value, underserved segments with limited existing competition.

Cannabinoid Product Opportunities in Animal Health

A growing body of real-world evidence on CBD and cannabinoid use in animals
Growing bank of early-stage cannabinoid clinical research around the world
Growing industry engagement with cannabinoid-based veterinary products

Powered by the Brains Bio Platform

The animal health division draws on the same EU-GMP manufacturing platform, regulatory expertise and clinical development capabilities that support our human pharmaceutical and nutraceutical businesses.

Opportunity for first mover advantage in many markets

Jas Kalsi

An experienced Chartered Professional Accountant with over 30 years of experience in providing personal and corporate taxation, corporate restructuring, financing, public offering and human resources management services. Kalsi is the Chief Financial Officer for Brains Bioceutical Corp., a global manufacturer of naturally-sourced active pharmaceutical ingredients (APIs). In this role, Kalsi is responsible for overseeing and managing the fiscal health of the group, implementing best practices with respect to finance, accounting and internal controls, obtaining funding, providing recommendations on mergers and acquisitions and working collaboratively with the CEO and Board of Directors on strategy. In addition, Kalsi will be responsible to regulatory entities and authorities, including any security exchange commissions.

Kalsi was an audit partner at KPMG focusing on small, medium and large private, government sector and public audit clients. He was the Human Resource Manager in charge of recruiting, staff development and training, and a member of KPMG’s Professional Practice Group. Subsequent to KPMG, Kalsi was the Chief Financial Officer / Chief Executive Officer of a variety of private companies including 6.5 years with a pharmaceutical fulfillment provider and API developer.

Kalsi has a proven track record in hiring top-level senior executives, restructuring companies to minimize tax and maximize cash flows, raising financing and creating a cohesive culture.

Kalsi has a passion for wellness and has created several initiatives and partnered with several leading-edge individuals to help people create and enjoy the best versions of themselves. He sees the use cannabinoids as a major tool to facilitate one’s optimum lifestyle.

With the team and infrastructure in place, Brains Bioceutical has quickly become an industry leader in both the nutraceutical and pharmaceutical cannabinoid industries, with several clinical trials and academic studies underway evaluating the efficacy of cannabinoids to treat major diseases. Under Kalsi’s leadership, Brains Bioceutical has already established market dominance, as it is the only company in the world to sell bulk API commercially around the world, supporting both the pharmaceutical and wellness sectors. With ambitious plans to expand Brains Bioceutical into a global biotech company specializing in cannabinoid health and wellness solutions, Kalsi is pioneering a new frontier in medicinal and wellness solutions across the world.

Animal Health

Brains Bio is an early-mover in veterinary cannabinoid market with strong overlap in R&D, targeting co-development opportunities with accelerated routes to market.

Built on Clinical Science

Cannabinoid Product Opportunities in Animal Health

Powered by the Brains Bio Platform

Contact Us

General Inquiries:

Animal Health

Brains Bio is an early-mover in veterinary cannabinoid market with strong overlap in R&D, targeting co-development opportunities with accelerated routes to market.

Built on Clinical Science

Cannabinoid Product Opportunities in Animal Health

Powered by the Brains Bio Platform

Contact Us

General Inquiries:

Jas Kalsi

Chief Financial Officer

Jennifer Archibald

Chief Financial Officer

Barinder Bhullar

Senior Vice President, Corporate Affairs

William Purves

Chief Commercial Officer

Gurdeep Bains

VP of Business Development

Jorja’s Story

A father’s journey to saving his daughter’s life

Dr. Mike Bowen

Dr. Jack Taunton

Dr. Sharon Gurm

Dr. David Putrino

Dr. Gerry Ramogida

Norma Sebestyen

Dean Billington

COO

Terry O’Regan

President

Rick Brar

CEO and Chairman